Yahoo Web Search

  1. Yahoo Finance Results

  2. Revenue from Innovative Health was up 6 percent year-over-year to $8.2 billion, while revenue from Essential Health was down 7 percent year-over-year to $5.5 billion, some of which was a result ...

  3. GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs ...

    40.21+0.18 (+0.44%)

    at Mon, May 21, 2018, 10:10AM EST - U.S. Markets close in 4 hrs 50 mins

    Nasdaq Real Time Price

    • Open 40.09
    • High 40.22
    • Low 39.98
    • Prev. Close 40.03
    • 52 Wk. High 34.52
    • 52 Wk. Low 34.52
    • P/E 46.00
    • Mkt. Cap 98.79B
  4. Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

    Zacks via Yahoo FinanceMay 04 15:50 PM

    Emergent BioSolutions Inc. EBS incurred a loss of 3 cents per share in the first quarter of 2018, significantly missing the Zacks Consensus Estimate of earnings of 30 cents. Shares of Emergent ...

  5. Deals Bonanza in U.K. Poised to Hit a Record Amid Brexit Fears

    Bloomberg via Yahoo FinanceApr 30 15:55 PM

    Dealmaking by U.K. companies such as J Sainsbury Plc, GlaxoSmithKline Plc and Sky Plc is poised to hit a record this year amid a surge in both foreign takeover interest ...

  6. Merck & Co., Inc. MRK reported first-quarter 2018 adjusted earnings of $1.05 per share, which beat the Zacks Consensus Estimate of 99 cents by 6.1%. Including a $1.4 billion charge related to ...

  7. Designed to provide broad exposure to the European Equity ETFs category of the U.S. equity market, the First Trust STOXX European Select Dividend Index Fund (FDD) is a smart beta exchange traded fund launched on 08/27/2007.

  8. J&J’s JNJ multiple myeloma drug Darzalex gained FDA approval for combination use in first-line setting while Roche RHHBY announced a couple of regulatory/pipeline updates on its PD-L1 inhibitor ...

  9. Glaxo's Advair Is the $100 Billion Asthma Drug That Won't Die

    Bloomberg via Yahoo FinanceMay 04 4:00 AM

    Sharon Bassett tries to stretch a month’s supply of GlaxoSmithKline Plc’s Advair over 60 days to save money on the asthma treatment because the U.S. lacks a cheaper generic version ...

  10. AstraZeneca, plc’s AZN new asthma drug, Fasenra (benralizumab) did not meet the primary endpoint in a late-stage study evaluating the respiratory biologic medicine for an expanded indication ...

  11. GlaxoSmithKline Plc is cutting finance and accounting positions while bringing in people with cancer and science backgrounds as the U.K.’s biggest drug company shifts spending ...

  1. Ads
    related to Glaxosmithkline PLC